No Results Found
Try adjusting your search to find what you’re looking for.
11/09/2021
Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing
Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the completion of an oversubscribed and up-sized $215 million Series B financing. Including this round, the Company has raised over $300 million to date.
Read More
10/26/2021
DNA Script Raises $165M In Oversubscribed Series C Financing
DNA Script, a pioneer in Enzymatic DNA Synthesis (EDS) and DNA printing on demand, today announced it has raised $165 million in a Series C financing led by Coatue Management and Catalio Capital Management. The new funds will be used to accelerate expansion and commercialization of the company’s revolutionary SYNTAX Platform.
Read More
10/19/2021
Castle Biosciences to Acquire Cernostics
Castle Biosciences, Inc. (Nasdaq: CSTL), applying innovative diagnostics to transform disease management and improve patient outcomes, today announced it has signed a definitive agreement to acquire Cernostics, Inc. (Cernostics), an Illumina Ventures company. Cernostics specializes in spatial biology and artificial intelligence-driven image analysis of tissue biopsies. Its TissueCypher® ...
Read More
10/18/2021
RedShift BioAnalytics Closes $20M Series E Funding Led by Illumina Ventures
RedShift BioAnalytics Inc. (RedShiftBioⓇ), a company providing next-generation platform technology enabling measurement of previously undetectable structure changes in biomolecules, announced today the closing of its Series E Preferred Stock financing. The $20 million financing was led by Illumina Ventures and joined by all of the company’s current major investors, including Technology Venture ...
Read More